a single, sole source manufacturer to make the NXP900 drug substance and another single, sole source manufacturer to make the NXP900 finished drug product
In August 2021, the Company entered into a worldwide, exclusive license agreement with the University of Edinburgh, Scotland for the Company's drug candidate NXP900
There have been no material changes to the CRT Pioneer Fund License Agreement, as previously disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025
Nuvectis Pharma, Inc. Customers
No clients on recordNo downstream customers found in our database for Nuvectis Pharma, Inc..
Nuvectis Pharma, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
NVCT-DEBT-11426
Warrants outstanding: 11192000
90%
xbrl warrant detail from xbrl 2023-12-31.
NVCT-DEBT-11427
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
Nuvectis Pharma, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Nuvectis Pharma, Inc..
Nuvectis Pharma, Inc. Ownership
Holder
Name
Confidence
Evidence
NVCT-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 63 tracked holders.
Nuvectis Pharma, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
